Integrase inhibitors are a class of antiretroviral drug developed for the treatment of HIV infection. They block the action of integrase, an enzyme that integrates genetic material from the virus into its target cell. No integrase inhibitors have yet received governmental approval, although two are currently undergoing testing.
Drugs under development
- MK-0518, developed by Merck & Co., has entered Phase III clinical trials.
- GS 9137 or JTK-303, licensed by Gilead Sciences from Japan Tobacco.
- MK-0518, the first Integrase Inhibitor for HIV
- HIV Antiretroviral Agents in Development
- integrase+inhibitors at the US National Library of Medicine Medical Subject Headings (MeSH)
- Savarino A. A historical sketch of the discovery and development of HIV-1 integrase inhibitors. Expert Opin Investig Drugs. 2006 Dec;15(12):1507-22. ]